

A Hugh Mostafid

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4835111/a-hugh-mostafid-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

92
papers

3,073
citations

28
h-index

54
g-index

113
ext. papers

4,509
ext. citations

4.8
avg. IF

5.34
L-index

#	Paper	IF	Citations
92	Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.. <i>European Urology</i> , 2022 ,	10.2	2
91	En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. <i>World Journal of Urology</i> , 2021 , 39, 3353-3358	4	3
90	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021 , 4, 182-191	6.7	15
89	En Bloc Resection of Bladder Tumor-Is It the Way Forward?. <i>Frontiers in Surgery</i> , 2021 , 8, 685506	2.3	
88	Diagnostic accuracy of ultrasonography, computed tomography, cystoscopy and cytology to detect urinary tract malignancies in patients with asymptomatic hematuria. <i>World Journal of Urology</i> , 2021 , 39, 97-103	4	8
87	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. <i>European Urology</i> , 2021 , 79, 62-79	10.2	176
86	Early recurrence and the need for re-resection following Photodynamic diagnosis-Assisted Transurethral Resection of Bladder Tumours: Multi-centre real-world experience of the UK PDD Users Group. <i>Journal of Clinical Urology</i> , 2021 , 14, 65-72	0.2	
85	Best Practices to Optimise Quality and Outcomes of Transurethral Resection of Bladder Tumours. <i>European Urology Oncology</i> , 2021 , 4, 12-19	6.7	11
84	What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?. <i>BJU International</i> , 2021 , 128, 225-235	5.6	2
83	Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 ,	2.8	4
82	Alternating Cystoscopy with Bladder EpiCheck [®] in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. <i>Bladder Cancer</i> , 2021 , 7, 307-315	1	1
81	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). <i>European Urology</i> , 2021 ,	10.2	51
80	The IDENTIFY study: the investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer - a multicentre observational study. <i>BJU International</i> , 2021 , 128, 440-450	5.6	4
79	Management of NMIBC during BCG shortage and COVID-19. <i>Trends in Urology & Ments Health</i> , 2021 , 12, 7-11	0.3	0
78	An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. <i>European Urology</i> , 2020 , 78, 546-569	10.2	30
77	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2020 , 125, 817-826	5.6	12
76	IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study. <i>International Journal of Surgery Protocols</i> , 2020 , 21, 8-12	1.1	2

75	TULA in recurrent non-muscle invasive bladder cancer. <i>Trends in Urology & Ments Health</i> , 2020 , 11, 18-19	0.3	
74	Exploring patientsRexperience and perception of being diagnosed with bladder cancer: a mixed-methods approach. <i>BJU International</i> , 2020 , 125, 669-678	5.6	11
73	Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guñin shortage. <i>Current Opinion in Urology</i> , 2020 , 30, 365-369	2.8	15
72	Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance. <i>BMJ Open</i> , 2020 , 10, e041005	3	6
71	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 440-448	2.8	14
70	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort: Under the Auspices of the EAU-ESMO Guidelines Committees. <i>European Urology</i> , 2020 , 77, 223-250	10.2	60
69	Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. <i>European Urology</i> , 2020 , 78, 893-906	10.2	35
68	Indications and Complications of Androgen Deprivation Therapy. <i>Seminars in Oncology Nursing</i> , 2020 , 36, 151042	3.7	0
67	Rapid, Low-Cost Dielectrophoretic Diagnosis of Bladder Cancer in a Clinical Setting. <i>IEEE Journal of Translational Engineering in Health and Medicine</i> , 2020 , 8, 4300405	3	4
66	Consensus Definition and Prediction of Complexity in Transurethral Resection or Bladder Endoscopic Dissection of Bladder Tumours. <i>Cancers</i> , 2020 , 12,	6.6	4
65	Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel. <i>European Urology Focus</i> , 2020 , 6, 479-489	5.1	39
64	Mixed-methods approach to exploring patientsRperspectives on the acceptability of a urinary biomarker test in replacing cystoscopy for bladder cancer surveillance. <i>BJU International</i> , 2019 , 124, 408-417	5.6	9
63	Does urinary cytology have a role in haematuria investigations?. <i>BJU International</i> , 2019 , 123, 74-81	5.6	20
62	European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. <i>European Urology</i> , 2019 , 76, 639-657	10.2	53
61	Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 5818-5831	12.9	43
60	Emerging Immunotherapy Options for bacillus Calmette-Guñin Unresponsive Nonmuscle Invasive Bladder Cancer. <i>Journal of Urology</i> , 2019 , 202, 1111-1119	2.5	17
59	Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness. <i>BMJ Open</i> , 2019 , 9, e022268	3	8
58	EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees. <i>Annals of Oncology</i> , 2019 , 30, 1697-1727	10.3	28

57	Intravesical BCG: where do we stand? Past, present and future. <i>Journal of Clinical Urology</i> , 2019 , 12, 425-435	1
56	Development and validation of a haematuria cancer risk score to identify patients at risk of harbouring cancer. <i>Journal of Internal Medicine</i> , 2019 , 285, 436-445	10.8 12
55	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019 , 123, 947-958	5.6 8
54	BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). <i>European Urology</i> , 2019 , 75, 593-601	10.2 16
53	Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non-muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. <i>European Urology</i> , 2019 , 75, 63-71	10.2 57
52	Oncological Outcomes of Laparoscopic Nephroureterectomy Versus Open Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An European Association of Urology Guidelines Systematic Review. <i>European Urology Focus</i> , 2019 , 5, 205-223	5.1 66
51	Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". <i>European Urology Focus</i> , 2019 , 5, 457-466	5.1 73
50	Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2019 , 5, 224-241	5.1 33
49	Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. <i>European Urology</i> , 2018 , 74, 10-14	10.2 49
48	Correction to: Meeting abstracts from the 4th International Clinical Trials Methodology Conference (ICTMC) and the 38th Annual Meeting of the Society for Clinical Trials. <i>Trials</i> , 2018 , 19,	2.8 78
47	Can Renal and Bladder Ultrasound Replace Computerized Tomography Urogram in Patients Investigated for Microscopic Hematuria?. <i>Journal of Urology</i> , 2018 , 200, 973-980	2.5 39
46	Prevention of bladder cancer incidence and recurrence: nutrition and lifestyle. <i>Current Opinion in Urology</i> , 2018 , 28, 88-92	2.8 27
45	European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. <i>European Urology</i> , 2018 , 73, 111-122	10.2 507
44	Guideline of guidelines: asymptomatic microscopic haematuria. <i>BJU International</i> , 2018 , 121, 176-183	5.6 53
43	Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients. <i>Bladder Cancer</i> , 2018 , 4, 395-401	1 35
42	Indication for a Single Postoperative Instillation of Chemotherapy in Non-muscle-invasive Bladder Cancer: What Factors Should Be Considered?. <i>European Urology Focus</i> , 2018 , 4, 525-528	5.1 4
41	What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence. <i>Current Opinion in Urology</i> , 2018 , 28, 570-576	2.8 11
40	Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. <i>European Urology</i> , 2017 , 72, 891-913	10.2 124

39	A core outcome set for localised prostate cancer effectiveness trials. <i>BJU International</i> , 2017 , 120, E64-E70	3.9	34
38	Reply to Harry Herrick Letter to the Editor re: Marko Babjuk, Andreas Bille, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. <i>Eur Urol</i> 2017 ;71:447-61. <i>European Urology</i> , 2017 , 71, e173-e174	10.2	6
37	Advances in intravesical drug delivery systems to treat bladder cancer. <i>International Journal of Pharmaceutics</i> , 2017 , 532, 105-117	6.5	37
36	Phase I/II cancer study: Oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16016-e16016	2.7	5
35	Diagnosis and treatment of non-muscle-invasive bladder cancer. <i>Trends in Urology & Mens Health</i> , 2015 , 6, 23-27	0.3	2
34	The Safe and Economical Care of Ta Bladder Cancer. <i>Urology Practice</i> , 2014 , 1, 176-183	0.8	1
33	Does the nonurologic scientific community understand urothelial bladder cancer?. <i>European Urology</i> , 2014 , 66, 601-2	10.2	4
32	Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. <i>Journal of Clinical Urology</i> , 2014 , 7, 90-98	0.2	10
31	BCG immunotherapy for bladder cancer--the effects of substrain differences. <i>Nature Reviews Urology</i> , 2013 , 10, 580-8	5.5	49
30	Measuring and improving the quality of transurethral resection for bladder tumour (TURBT). <i>BJU International</i> , 2012 , 109, 1579-82	5.6	22
29	Mesh erosion following laparoscopic incisional hernia repair. <i>Hernia: the Journal of Hernias and Abdominal Wall Surgery</i> , 2012 , 16, 223-6	3.2	12
28	Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. <i>British Journal of Cancer</i> , 2012 , 106, 496-507	8.7	25
27	Quality improvement in multidisciplinary cancer teams: an investigation of teamwork and clinical decision-making and cross-validation of assessments. <i>Annals of Surgical Oncology</i> , 2011 , 18, 3535-43	3.1	80
26	Is it time to re-design the haematuria clinic?. <i>BJU International</i> , 2010 , 105, 585-8	5.6	10
25	The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer. <i>BJU International</i> , 2010 , 105 Suppl 2, 2-7	5.6	9
24	Editorial comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. <i>International Journal of Urology</i> , 2010 , 17, 766-7	2.3	
23	Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. <i>European Urology</i> , 2010 , 57, 607-14	10.2	90
22	Immediate Postoperative Instillation of Intravesical Mitomycin in Theatre: Outcome and Effect on Recurrence of Non Muscle-Invasive Bladder Cancer. <i>Current Urology</i> , 2009 , 3, 72-75	1.7	

21	Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. <i>BJU International</i> , 2009 , 103, 726-9	5.6	9
20	Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305). <i>BJU International</i> , 2009 , 104, 889-90	5.6	7
19	The Use of the NMP22 BladderChek Test for Bladder Cancer to Optimise Investigations in a One-Stop Haematuria Clinic. <i>British Journal of Medical and Surgical Urology</i> , 2008 , 1, 126-130		5
18	Case report: differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-Guérin treatment for high-risk superficial bladder cancer. <i>International Urology and Nephrology</i> , 2007 , 39, 1039-41	2.3	2
17	The management of hydronephrosis in patients undergoing TURBT. <i>International Urology and Nephrology</i> , 2006 , 38, 483-6	2.3	4
16	Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. <i>BJU International</i> , 2006 , 97, 509-12	5.6	18
15	Measles, mumps and rubella -- the urologist's perspective. <i>International Journal of Clinical Practice</i> , 2006 , 60, 335-9	2.9	12
14	RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS. <i>Journal of Urology</i> , 2005 , 173, 1433-1433	2.5	2
13	Planning percutaneous nephrolithotomy using multidetector computed tomography urography, multiplanar reconstruction and three-dimensional reformatting. <i>BJU International</i> , 2005 , 95, 1280-4	5.6	66
12	Do patients with frank haematuria referred under the two-week rule have a higher incidence of bladder cancer?. <i>Annals of the Royal College of Surgeons of England</i> , 2005 , 87, 345-7	1.4	6
11	Emergency dorsal slit for balanitis with retention. <i>Journal of the Royal Society of Medicine</i> , 2004 , 97, 205-6	3	2
10	A novel device for reconstituting and delivering intravesical chemotherapy. <i>BJU International</i> , 2003 , 92, 492	5.6	2
9	The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs transurethral resection of the prostate. <i>BJU International</i> , 2001 , 88, 217-20	5.6	15
8	The self-expanding metallic ureteric stent in the long-term management of benign ureteric strictures. <i>BJU International</i> , 2001 , 88, 339-42	5.6	36
7	The responsiveness of the ICSmale questionnaire to outcome: evidence from the ICS-IBPHR study. <i>BJU International</i> , 1999 , 83, 243-8	5.6	17
6	Radio-contrast enhancement of a urinary tract calculus. <i>Urologia Internationalis</i> , 1999 , 62, 127-9	1.9	2
5	Leydig cell tumour of the testis: a rare cause of male infertility. <i>BJU International</i> , 1998 , 81, 651	5.6	5
4	The testicular tumour of adrenogenital syndrome: an unusual cause of male infertility. <i>BJU International</i> , 1998 , 81, 649-50	5.6	1

3	Re: Possible mechanisms of action of transurethral needle ablation of the prostate on benign prostatic hyperplasia symptoms: a neurohistochemical study. <i>Journal of Urology</i> , 1998 , 159, 209-10	2.5	
2	A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. <i>BJU International</i> , 1997 , 80, 116-22	5.6	15
1	Interstitial Radiofrequency Therapy of the Prostate: Results of a Pilot Study. <i>Journal of Urology</i> , 1996 , 155, 1946-1949	2.5	3